All on track with FY 2022 results, becoming commercial at YE
Onward reported FY 2022 results and provided an outlook for 2023. Most significantly, the company confirmed i) that it is on track to receive the first FDA approval for ARC-EX for upper mobility after spinal cord injury (SCI) around YE 2023, ii) publish detailed ARC-EX Up-LIFT pivotal study data du
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.